Allergan, Inc. (AGN), Sanofi SA (ADR) (SNY): New FDA Guidelines Hit This Company Hard

The FDA’s response to Allergan’s letter is anybody’s guess, but at least Allergan has its flagship product Botox to bank upon, which is growing. With the recent FDA approval in January for treatment of overactive bladder, Botox is now approved in the U.S. for seven therapeutic indications . Approved worldwide for 26 indications in 85 countries, 52% of overall Botox sales in 2012 pertained to therapeutic sales, with U.S. sales registering a 13% increase.

The investing takeaway

With 47% of revenue coming from ophthalmology, 16% from therapeutic, 15% from cosmetic Botox, and the rest from skin and breast aesthetics and obesity intervention, Allergan has a balanced product portfolio.

Allergan’s shares have rebounded recently, and while I wonder whether the FDA will change its stance on this issue, Allergan has other opportunities that make it an interesting stock to add to your watchlist.

The article New FDA Guidelines Hit This Company Hard originally appeared on Fool.com and is written by Kanak Kanti De.

Kanak Kanti De has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.